DYSPORT (abobotulinumtoxinA) is a prescription injectable drug that temporarily improves the look of frown lines between the eyes of adults under 65 years of age. There are certain medical conditions that may be in contradiction with the use of DYSPORT.
Swallowing or breathing difficulties can occur with the treatment of DYSPORT. Since the treatment of DYSPORT in patients with cervical dystonia weakens neck muscles, including those muscles that serve a ventilation function, it may result in a loss of breathing capacity in some patients.
A patient with a pre-existing condition of dysphagia (difficulty in swallowing), may be more likely to develop complications with the use of DYSPORT or develop a more severe swallowing disorder.
Any person that has pre-existing respiratory issues and has breathing difficulties, is at more at risk of these symptoms to be exasperated with typical doses of DYSPORT.
A DYSPORT candidate that has been diagnosed with a neuromuscular disorder, such as amyotrophic lateral sclerosis (ALS), Lambert-Eaton syndrome or myasthenia gravis, should be closely monitored while on DYSPORT. People with these conditions are at increased risk of respiratory and dysphagia problems when taking DYSPORT.
Pregnancy and Breastfeeding
Since there is no known data on DYSPORT in pregnant women, pregnant women are urged to justify the benefit of using DYSPORT with the potential risk to their unborn baby. To date, there is no scientific evidence to support whether DYSPORT is excreted in human milk.
To date, there is insufficient data on the use of DYSPORT in patients over 65 years of age. Elderly patients over 65 years of age should be closely monitored while using DYSPORT drug therapy.